These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696 [TBL] [Abstract][Full Text] [Related]
3. Current status of adjuvant therapy for pancreatic cancer. Katz MH; Fleming JB; Lee JE; Pisters PW Oncologist; 2010; 15(11):1205-13. PubMed ID: 21045189 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. Twombly R J Natl Cancer Inst; 2008 Dec; 100(23):1670-1. PubMed ID: 19033566 [No Abstract] [Full Text] [Related]
5. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant therapy in curable pancreatic cancer. Nugent FW; Stuart K Surg Clin North Am; 2010 Apr; 90(2):323-39. PubMed ID: 20362789 [TBL] [Abstract][Full Text] [Related]
8. The recent past and future of adjuvant therapy for pancreatic cancer. Yeo CJ Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012 [No Abstract] [Full Text] [Related]
9. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947 [TBL] [Abstract][Full Text] [Related]
11. Update on adjuvant trials for pancreatic cancer. Backlund DC; Berlin JD; Parikh AA Surg Oncol Clin N Am; 2010 Apr; 19(2):391-409. PubMed ID: 20159521 [TBL] [Abstract][Full Text] [Related]
12. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Yang A; O'Reilly EM Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370 [TBL] [Abstract][Full Text] [Related]
13. [Chemoradiation for pancreatic adenocarcinoma]. Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252 [TBL] [Abstract][Full Text] [Related]
14. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
15. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant strategies for pancreatic cancer. Ghaneh P; Smith R; Tudor-Smith C; Raraty M; Neoptolemos JP Eur J Surg Oncol; 2008 Mar; 34(3):297-305. PubMed ID: 17936564 [TBL] [Abstract][Full Text] [Related]
17. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Fogelman DR; Chen J; Chabot JA; Allendorf JD; Schrope BA; Ennis RD; Schreibman SM; Fine RL Surg Oncol Clin N Am; 2004 Oct; 13(4):711-35, x. PubMed ID: 15350944 [TBL] [Abstract][Full Text] [Related]
18. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M; J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219 [TBL] [Abstract][Full Text] [Related]